{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:25:18Z","timestamp":1784719518089,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019708","name":"UroGen Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04821-5","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:47:56Z","timestamp":1760158076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of UGN\u2011102, an investigational mitomycin\u2011containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"95","author":[{"given":"Sandip M.","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Tsurutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikky","family":"Ugwuoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalit","family":"Strauss-Ayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"issue":"1","key":"4821_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4821_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","volume":"37","author":"LL Monteiro","year":"2019","unstructured":"Monteiro LL et al (2019) ICUD-SIU international consultation on bladder cancer 2017: management of non-muscle invasive bladder cancer. World J Urol 37(1):51\u201360","journal-title":"World J Urol"},{"issue":"4","key":"4821_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM et al (2024) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol 211(4):533\u2013538","journal-title":"J Urol"},{"issue":"4","key":"4821_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196(4):1021\u20131029","journal-title":"J Urol"},{"issue":"5","key":"4821_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan WS et al (2022) Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group. Eur Urol Oncol 5(5):505\u2013516","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"4821_CR6","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/S0022-5347(05)68075-5","volume":"162","author":"B Leblanc","year":"1999","unstructured":"Leblanc B et al (1999) Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162(6):1946\u20131950","journal-title":"J Urol"},{"key":"4821_CR7","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A et al (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 384:e076743","journal-title":"BMJ"},{"issue":"1","key":"4821_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12885-024-11874-x","volume":"24","author":"S Jing","year":"2024","unstructured":"Jing S et al (2024) Perioperative outcomes and continence following robotic-assisted radical cystectomy with Mainz pouch II urinary diversion in patients with bladder cancer. BMC Cancer 24(1):127","journal-title":"BMC Cancer"},{"issue":"1","key":"4821_CR9","first-page":"139","volume":"4","author":"X Gao","year":"1998","unstructured":"Gao X et al (1998) Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 4(1):139\u2013143","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4821_CR10","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/cancers16101843","volume":"16","author":"S McNall","year":"2024","unstructured":"McNall S et al(2024) Treatment modalities for non-muscle invasive bladder cancer: an updated review. Cancers (Basel) 16(10):1843. https:\/\/doi.org\/10.3390\/cancers16101843","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4821_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"6","key":"4821_CR12","first-page":"Cd009294","volume":"6","author":"MA Han","year":"2021","unstructured":"Han MA et al (2021) Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 6(6):Cd009294","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"4821_CR13","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.urolonc.2018.08.004","volume":"36","author":"SA Yap","year":"2018","unstructured":"Yap SA et al (2018) Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. Urol Oncol 36(11):498.e1-498.e7","journal-title":"Urol Oncol"},{"key":"4821_CR14","unstructured":"MITOMYCIN USPI. Available at: https:\/\/www.drugs.com\/pro\/mitomycin.html.Accessed November (2024)"},{"issue":"11","key":"4821_CR15","first-page":"1633","volume":"60","author":"ST Crooke","year":"1976","unstructured":"Crooke ST et al (1976) Phase I study of oral mitomycin C. Cancer Treat Rep 60(11):1633\u20131636","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"4821_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ijc.2910510305","volume":"51","author":"EA De Bruijn","year":"1992","unstructured":"De Bruijn EA et al (1992) Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 51(3):359\u2013364","journal-title":"Int J Cancer"},{"issue":"10","key":"4821_CR17","first-page":"5017","volume":"43","author":"J den Hartigh","year":"1983","unstructured":"den Hartigh J et al (1983) Pharmacokinetics of mitomycin C in humans. Cancer Res 43(10):5017\u20135021","journal-title":"Cancer Res"},{"issue":"19","key":"4821_CR18","first-page":"5144","volume":"51","author":"JT Dalton","year":"1991","unstructured":"Dalton JT et al (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51(19):5144\u20135152","journal-title":"Cancer Res"},{"issue":"3","key":"4821_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00269026","volume":"13","author":"RB Schilcher","year":"1984","unstructured":"Schilcher RB et al (1984) Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol 13(3):186\u2013190","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4821_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00389973","volume":"113","author":"J Verweij","year":"1987","unstructured":"Verweij J et al (1987) Relationship between clinical parameters and pharmacokinetics of mitomycin C. J Cancer Res Clin Oncol 113(1):91\u201394","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"4821_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.urology.2013.03.036","volume":"82","author":"M Maffezzini","year":"2013","unstructured":"Maffezzini M et al (2013) Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer. Urology 82(2):400\u2013404","journal-title":"Urology"},{"issue":"3","key":"4821_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","volume":"52","author":"R Paroni","year":"2001","unstructured":"Paroni R et al (2001) Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 52(3):273\u2013278","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"4821_CR23","first-page":"3314","volume":"53","author":"MG Wientjes","year":"1993","unstructured":"Wientjes MG et al (1993) Penetration of mitomycin C in human bladder. Cancer Res 53(14):3314\u20133320","journal-title":"Cancer Res"},{"issue":"4","key":"4821_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JU.0000000000003645","volume":"210","author":"SM Prasad","year":"2023","unstructured":"Prasad SM et al (2023) Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 +\/- transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J Urol 210(4):619\u2013629","journal-title":"J Urol"},{"issue":"2","key":"4821_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000004296","volume":"213","author":"SM Prasad","year":"2025","unstructured":"Prasad SM et al (2025) Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J Urol 213(2):205\u2013216","journal-title":"J Urol"},{"key":"4821_CR26","unstructured":"FDA, FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Available at: Accessed July (202 5). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle"},{"issue":"1","key":"4821_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/JU.0000000000002186","volume":"207","author":"KK Chevli","year":"2022","unstructured":"Chevli KK et al (2022) Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial. J Urol 207(1):61\u201369","journal-title":"J Urol"},{"issue":"3","key":"4821_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","volume":"9","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T et al(2023) A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer. Eur Urol Focus 9(3):463\u2013479","journal-title":"Eur Urol Focus"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04821-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:02:06Z","timestamp":1760202126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04821-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4821"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04821-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SMP has received PI funding from Janssen, Merck, Pfizer, and UroGen Pharma. DSA, VT, MK, MJL, BB, and NU are UroGen Pharma employees, and may hold stock and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice and the Declaration of Helsinki and was approved by the designated ethics committees and institutional review boards at each study site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"100"}}